Open Access Open Access  Restricted Access Subscription Access

Objectives, Symptoms, Mechanism of Action and Administration of Lipid Lowering Drug Therapy

Muralinath E., Madhavi Latha C., Ramadevi. Ch., Sheethal U., Guruprasad M., Karthik Jayanth Y., Renuka U., Sony Sharlet E.

Abstract


When it comes to lowering the risk of significant cardiovascular events, such as cardiovascular death, nonfatal myocardial infarction, stroke, coronary revascularization, and unstable angina, lipid-lowering medication therapy is crucial. These drugs work well for both primary and secondary inhibition, and they work best when combined with lifestyle changes. A thorough review of lipid-lowering medications, including well-known classes like statins, bile acid sequestrants, niacin, fibrates, and cholesterol absorption inhibitors, is organized in this activity. This activity also examines the expanding field of advanced therapeutics along with PCSK9 inhibitors, small-interfering RNA agents, microsomal triglyceride transfer protein inhibitors as well as antisense oligonucleotides. Together, these therapies provide valuable options for patients along with familial hypercholesterolemia or those unable to attain lipid targets along with traditional agents, thereby promoting long-term cardiovascular outcomes.


Full Text:

PDF

References


Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., ... Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139(25), e1082–e1143. https://doi.org/10.1161/CIR.0000000000000625

Sizar, O., Nassereddin, A., & Talati, R. (2023). Ezetimibe. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK532879/

Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., Wilt, T. J., & Wittes, J. (1999). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. The New England Journal of Medicine, 341(6), 410–418. https://doi.org/10.1056/NEJM199908053410604

Wang, D., Liu, B., Tao, W., Hao, Z., & Liu, M. (2015). Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database of Systematic Reviews, 2015(10), CD009580. https://doi.org/10.1002/14651858.CD009580.pub2

Probstfield, J. L., & Hunninghake, D. B. (1994). Nicotinic acid as a lipoprotein-altering agent: Therapy directed by the primary physician. Archives of Internal Medicine, 154(14), 1557–1559.

Grundy, S. M., Mok, H. Y., Zech, L., & Berman, M. (1981). Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. Journal of Lipid Research, 22(1), 24–36.

Handelsman, Y. (2011). Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care, 34(Suppl. 2), S244–S250. https://doi.org/10.2337/dc11-s229

Yang, Y., Hwang, S., Kim, M., Lim, Y., Kim, M. H., Lee, S., Lim, D. J., Kang, M. I., & Cha, B. Y. (2015). Refractory Graves' disease successfully cured by adjunctive cholestyramine and subsequent total thyroidectomy. Endocrinology and Metabolism, 30(4), 620–625. https://doi.org/10.3803/EnM.2015.30.4.620

Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J. T., Kaplan, C., Zhao, X. Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990). Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. The New England Journal of Medicine, 323(19), 1289–1298. https://doi.org/10.1056/NEJM199011083231901

Knapp, H. H., Schrott, H., Ma, P., Knopp, R., Chin, B., Gaziano, J. M., Donovan, J. M., Burke, S. K., & Davidson, M. H. (2001). Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. The American Journal of Medicine, 110(5), 352–360. https://doi.org/10.1016/S0002-9343(00)00731-9

Pravastatin Multicenter Study Group II. (1993). Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Archives of Internal Medicine, 153(11), 1321–1329.

Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024). Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside. Signal Transduction and Targeted Therapy, 9(1), 13. https://doi.org/10.1038/s41392-023-01705-z

Xiao, G., Gao, S., Xie, Y., Wang, Z., & Shu, M. (2024). Efficacy and safety of evolocumab and alirocumab as PCSK9 inhibitors in pediatric patients with familial hypercholesterolemia: A systematic review and meta-analysis. Medicina, 60(10). https://doi.org/10.3390/medicina60101659

Ma, H., Ma, W., Liu, Y., Chen, L., & Ding, P. (2025). Effects of alirocumab and evolocumab on cardiovascular mortality and LDL-C: Stratified according to the baseline LDL-C levels. Reviews in Cardiovascular Medicine, 26(4).

Wright, R. S., Raal, F. J., Koenig, W., Landmesser, U., Leiter, L. A., Vikarunnessa, S., Lesogor, A., Maheux, P., Talloczy, Z., Zang, X., Schwartz, G. G., & Ray, K. K. (2024). Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: The ORION-8 trial. Cardiovascular Research, 120(12), 1400–1410. https://doi.org/10.1093/cvr/cvae143

Taub, P. R., Gutierrez, A., Wewers, D., Garcia Cantu, E., Cao, H., Deck, C., Lesogor, A., Ott, D., Mena-Madrazo, J., Zang, X., & Wright, R. S. (2025). Safety and lipid-lowering efficacy of inclisiran monotherapy in patients without ASCVD: The VICTORION-Mono randomized clinical trial. Journal of the American College of Cardiology, 86(3), 196–208.

Alaíz, Á. R., Gudino, L. C., de la Isla, L. P., Pardo, H. G., Calle, D. G., & Miramontes-González, J. P. (2025). Inclisiran: Efficacy in real world—Systematic review and meta-analysis. Journal of Clinical Medicine, 14(12). https://doi.org/10.3390/jcm14124337

Kulshreshtha, M. (2022). An update on new cholesterol inhibitor: Bempedoic acid. Current Cardiology Reviews, 18(2), e141221198875. https://doi.org/10.2174/1573403X18666211214145155

De Filippo, O., D'Ascenzo, F., Iannaccone, M., Bertaina, M., Leone, A., Borzillo, I., Ravetti, E., Solano, A., Pagliassotto, I., Nebiolo, M., Bruno, F., Giacobbe, F., Muscoli, S., Monticone, S., Brizzi, M. F., Biondi-Zoccai, G., & De Ferrari, G. M. (2023). Safety and efficacy of bempedoic acid: A systematic review and meta-analysis of randomized controlled trials. Cardiovascular Diabetology, 22(1), 324. https://doi.org/10.1186/s12933-023-02083-8

Bhagavathula, A. S., Al Matrooshi, N. O., Clark, C. C. T., & Rahmani, J. (2021). Bempedoic acid and ezetimibe for the treatment of hypercholesterolemia: A systematic review and meta-analysis of randomized phase II/III trials. Clinical Drug Investigation, 41(1), 19–28. https://doi.org/10.1007/s40261-020-00978-2


Refbacks

  • There are currently no refbacks.